tradingkey.logo
tradingkey.logo
検索

Glaukos Corp

GKOS
ウォッチリストに追加
144.420USD
0.0000.00%
終値 06/26, 16:00ET15分遅れの株価
8.43B時価総額
損失額直近12ヶ月PER

詳細情報 Glaukos Corp 企業名

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Glaukos Corpの企業情報

企業コードGKOS
会社名Glaukos Corp
上場日Jun 25, 2015
最高経営責任者「CEO」Burns (Thomas William)
従業員数995
証券種類Ordinary Share
決算期末Jun 25
本社所在地1 Glaukos Way
都市ALISO VIEJO
証券取引所NASDAQ OMX NASDAQ Basic NYSE
United States of America
郵便番号92656
電話番号19493679600
ウェブサイトhttps://www.glaukos.com
企業コードGKOS
上場日Jun 25, 2015
最高経営責任者「CEO」Burns (Thomas William)

Glaukos Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%

よくある質問

Glaukos Corpの上位5名の株主は誰ですか?

Glaukos Corpの上位5名の株主は以下のとおりです。Mr. Thomas William Burns

Glaukos Corp(GKOS)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Glaukos Corpの株式を保有している機関は702社あり、保有株式の総市場価値は約59.35Mで、全体の101.04%を占めています。2025Q4と比較して、機関の持ち株は-2784097.00増加しています。

Glaukos Corpの最大の収益源は何ですか?

2026Q1において、Glaucoma部門がGlaukos Corpにとって最大の収益を生み出しており、その金額は421.07Mで、全収益の82.98%を占めています。
KeyAI